Serametrix provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients. In partnership with the Ludwig Institute for Cancer Research (LICR) and other leading institutes Serametrix has developed a suite of immunoassays that monitor anti-tumor immunity in patients enrolled into clinical trials for novel cancer therapies. Serametrix is part owned by the LICR.

We standardize and provide access to proven technologies from trusted leaders in the field of immunooncology. As a commercial entity we excel in combining technical expertise with practical deliverability to move the clinical development of new drugs forward faster and more efficiently.

Our Immune Monitoring Package measures different elements of the immune system to help scientists, clinicians, and physicians understand the interaction between the patient’s immune system and the cancer during clinical development of new drugs. We screen patient samples in all phases of clinical trials with our immune monitoring assays and deliver data that provide comprehensive measures of anti-tumor immunity.

Mission Statement

Serametrix’s immediate mission is to standardize immune monitoring technologies developed in academic laboratories and to provide drug companies with access to these technologies in support of clinical trials to monitor the impact of cancer drugs on patient anti-tumor immunity.